Laura Vitale

TL;DR: This first-in-human study of a protein vaccine targeting dendritic cell receptor DEC-205 demonstrates its feasibility, safety, and biological activity and provides rationale for combination immunotherapy strategies including immune checkpoint blockade.

TL;DR: Observations support the development of CTLA-4 blockade for human immunotherapy and banishes the possibility of monkey anti-human Ab responses in the monkeys.

TL;DR: It is shown that hMR targeting induced both humoral and cellular antigenic specific immunity, which supports the clinical development of immunotherapeutic approaches in cancer using pattern recognition receptor targeting systems for the selective delivery of tumor Ags to APCs.

TL;DR: Great immune responses and clinical benefit, including the longest duration of stable disease, were observed with immunization combined with local TLR agonists, which has implications for enhancing the efficacy of cancer immunotherapy.

TL;DR: Preclinical evidence is provided that in vivo hDEC205 targeting increases the efficiency with which proteins elicit specific immunity, setting the stage for proof-of-concept studies of these new protein vaccines in human subjects.